So far, only Pfizer/BioNTech vaccine has been used for vaccination of teenagers.
On July 20, the State Agency of Medicines reported that the European Medicines Agency has approved use of Moderna vaccines for 12-17 year old children. The vaccine has been studied on 3,732 teenagers.
Until July 31, 16 percent of teenagers aged 12-15, and 32 percent of teenagers aged 16-17 have received one vaccine dose.